Literature DB >> 29057301

Uncovering a novel pathway for p16 silencing: Therapeutic implications for lung cancer.

C Gamell1,2, T Gulati1,2, B Solomon1,3, S Haupt1,2, Y Haupt1,2,4,5.   

Abstract

A key step during onset of most cases of non-small cell lung cancer (NSCLC) is the loss of the tumor suppressor p16INK4a (best known as p16), commonly due to promoter hypermethylation. We recently reported a novel regulatory pathway involving E6-associated protein and cell division control protein 6, which provides a methylation-independent mechanism for p16 silencing in patients with a particularly aggressive form of NSCLC.

Entities:  

Keywords:  CDC6; E6AP; INK4/ARF; NSCLC; p16; tumor suppression

Year:  2017        PMID： 29057301      PMCID： PMC5644485          DOI： 10.1080/23723556.2017.1299273

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

1.  Reduced abundance of the E3 ubiquitin ligase E6AP contributes to decreased expression of the INK4/ARF locus in non-small cell lung cancer.

Authors:  Cristina Gamell; Twishi Gulati; Yaara Levav-Cohen; Richard J Young; Hongdo Do; Pat Pilling; Elena Takano; Neil Watkins; Stephen B Fox; Prudence Russell; Doron Ginsberg; Brendon J Monahan; Gavin Wright; Alex Dobrovic; Sue Haupt; Ben Solomon; Ygal Haupt
Journal:  Sci Signal       Date:  2017-01-10       Impact factor: 8.192

Review 2.  Hypermethylated DNA as a biomarker for colorectal cancer: a systematic review.

Authors:  S L Rasmussen; H B Krarup; K G Sunesen; I S Pedersen; P H Madsen; O Thorlacius-Ussing
Journal:  Colorectal Dis       Date:  2016-06       Impact factor: 3.788

3.  E6AP is required for replicative and oncogene-induced senescence in mouse embryo fibroblasts.

Authors:  Y Levav-Cohen; K Wolyniec; O Alsheich-Bartok; A-L Chan; S J Woods; Y-H Jiang; S Haupt; Y Haupt
Journal:  Oncogene       Date:  2011-09-19       Impact factor: 9.867

4.  An efficient high-throughput screening method for MYST family acetyltransferases, a new class of epigenetic drug targets.

Authors:  Hendrik Falk; Theresa Connor; Hong Yang; Karen J Loft; Joanne L Alcindor; George Nikolakopoulos; Regina N Surjadi; John D Bentley; Meghan K Hattarki; Olan Dolezal; James M Murphy; Brendon J Monahan; Thomas S Peat; Tim Thomas; Jonathan B Baell; John P Parisot; Ian P Street
Journal:  J Biomol Screen       Date:  2011-11-14

5.  Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis.

Authors:  Moritz Bennecke; Lydia Kriegl; Monther Bajbouj; Kristin Retzlaff; Sylvie Robine; Andreas Jung; Melek C Arkan; Thomas Kirchner; Florian R Greten
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

6.  MOZ (MYST3, KAT6A) inhibits senescence via the INK4A-ARF pathway.

Authors:  B N Sheikh; B Phipson; F El-Saafin; H K Vanyai; N L Downer; M J Bird; A J Kueh; R E May; G K Smyth; A K Voss; T Thomas
Journal:  Oncogene       Date:  2015-03-16       Impact factor: 9.867

7.  Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.

Authors:  Siân Jones; Xiaosong Zhang; D Williams Parsons; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; Hirohiko Kamiyama; Antonio Jimeno; Seung-Mo Hong; Baojin Fu; Ming-Tseh Lin; Eric S Calhoun; Mihoko Kamiyama; Kimberly Walter; Tatiana Nikolskaya; Yuri Nikolsky; James Hartigan; Douglas R Smith; Manuel Hidalgo; Steven D Leach; Alison P Klein; Elizabeth M Jaffee; Michael Goggins; Anirban Maitra; Christine Iacobuzio-Donahue; James R Eshleman; Scott E Kern; Ralph H Hruban; Rachel Karchin; Nickolas Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

8.  Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer.

Authors:  Steven A Belinsky; Donna M Klinge; Christine A Stidley; Jean-Pierre Issa; James G Herman; Thomas H March; Stephen B Baylin
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

9.  Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.

Authors:  Rosalyn A Juergens; John Wrangle; Frank P Vendetti; Sara C Murphy; Ming Zhao; Barbara Coleman; Rosa Sebree; Kristen Rodgers; Craig M Hooker; Noreli Franco; Beverly Lee; Salina Tsai; Igor Espinoza Delgado; Michelle A Rudek; Steven A Belinsky; James G Herman; Stephen B Baylin; Malcolm V Brock; Charles M Rudin
Journal:  Cancer Discov       Date:  2011-11-09       Impact factor: 39.397

10.  INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence.

Authors:  Sharon Brookes; Janice Rowe; Margarida Ruas; Susana Llanos; Paula A Clark; Martine Lomax; Marion C James; Radost Vatcheva; Stewart Bates; Karen H Vousden; David Parry; Nelleke Gruis; Nico Smit; Wilma Bergman; Gordon Peters
Journal:  EMBO J       Date:  2002-06-17       Impact factor: 11.598
  10 in total
  2 in total

1.  E6AP Promotes a Metastatic Phenotype in Prostate Cancer.

Authors:  Cristina Gamell; Ivona Bandilovska; Twishi Gulati; Arielle Kogan; Syer Choon Lim; Zaklina Kovacevic; Elena A Takano; Clelia Timpone; Arjelle D Agupitan; Cassandra Litchfield; Giovanni Blandino; Lisa G Horvath; Stephen B Fox; Scott G Williams; Andrea Russo; Enzo Gallo; Piotr J Paul; Catherine Mitchell; Shahneen Sandhu; Simon P Keam; Sue Haupt; Des R Richardson; Ygal Haupt
Journal:  iScience       Date:  2019-11-02

2.  Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis.

Authors:  Beatriz Andrea Otálora-Otálora; Daniel Alejandro Osuna-Garzón; Michael Steven Carvajal-Parra; Alejandra Cañas; Martín Montecino; Liliana López-Kleine; Adriana Rojas
Journal:  Biology (Basel)       Date:  2022-07-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.